Ionis Pharmaceuticals Inc (NASDAQ:IONS) Position Decreased by First Light Asset Management LLC

Share on StockTwits

First Light Asset Management LLC decreased its holdings in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 46.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 327,132 shares of the company’s stock after selling 284,030 shares during the period. Ionis Pharmaceuticals makes up 2.9% of First Light Asset Management LLC’s portfolio, making the stock its 11th biggest holding. First Light Asset Management LLC’s holdings in Ionis Pharmaceuticals were worth $21,025,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in Ionis Pharmaceuticals by 9.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 292,868 shares of the company’s stock valued at $15,827,000 after buying an additional 24,169 shares in the last quarter. Geode Capital Management LLC raised its position in Ionis Pharmaceuticals by 6.5% during the fourth quarter. Geode Capital Management LLC now owns 1,341,433 shares of the company’s stock valued at $72,517,000 after acquiring an additional 82,152 shares in the last quarter. Cetera Advisor Networks LLC bought a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $366,000. Raymond James Financial Services Advisors Inc. raised its position in Ionis Pharmaceuticals by 76.4% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 17,157 shares of the company’s stock valued at $1,393,000 after acquiring an additional 7,433 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new position in Ionis Pharmaceuticals during the first quarter valued at approximately $14,272,000. Institutional investors own 89.05% of the company’s stock.

In other Ionis Pharmaceuticals news, CEO Stanley T. Crooke sold 10,000 shares of the stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $70.25, for a total transaction of $702,500.00. Following the transaction, the chief executive officer now owns 79,634 shares in the company, valued at $5,594,288.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Spencer R. Berthelsen sold 15,000 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $63.67, for a total value of $955,050.00. Following the transaction, the director now owns 99,404 shares in the company, valued at approximately $6,329,052.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,210 shares of company stock worth $3,244,934. Corporate insiders own 2.40% of the company’s stock.

Shares of IONS stock opened at $62.71 on Friday. Ionis Pharmaceuticals Inc has a 12 month low of $43.27 and a 12 month high of $86.58. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $65.61 and its two-hundred day moving average is $69.41. The company has a market cap of $8.81 billion, a PE ratio of 21.19 and a beta of 1.97.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.26. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company had revenue of $164.00 million for the quarter, compared to the consensus estimate of $145.31 million. During the same quarter last year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. As a group, equities analysts expect that Ionis Pharmaceuticals Inc will post -0.02 EPS for the current fiscal year.

IONS has been the topic of several recent research reports. ValuEngine lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Sanford C. Bernstein raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research report on Tuesday, September 10th. Evercore ISI set a $76.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Finally, TheStreet lowered shares of Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $69.00.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

See Also: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Quadratic Interest Rate Volatility and Inflation Hedge ETF   Shares Down 0.1%
Quadratic Interest Rate Volatility and Inflation Hedge ETF Shares Down 0.1%
Northern Cobalt  Stock Price Down 15.7%
Northern Cobalt Stock Price Down 15.7%
Stelco  Trading 2.4% Higher
Stelco Trading 2.4% Higher
Public Service Enterprise Group Inc.  Receives Consensus Rating of “Hold” from Brokerages
Public Service Enterprise Group Inc. Receives Consensus Rating of “Hold” from Brokerages
$22.10 Million in Sales Expected for PDF Solutions, Inc.  This Quarter
$22.10 Million in Sales Expected for PDF Solutions, Inc. This Quarter
Curbstone Financial Management Corp Increases Stock Position in SPDR Nuveen Barclays Short Term Municipal Bond ETF
Curbstone Financial Management Corp Increases Stock Position in SPDR Nuveen Barclays Short Term Municipal Bond ETF


© 2006-2019 Ticker Report